RENEURON GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.375 GBX | -2.17% |
|
-.--% | -3.57% |
| Apr. 17 | ReNeuron Group Reports CFO Resignation | MT |
| Apr. 17 | ReNeuron CFO steps down to pursue other opportunities | AN |
Valuation
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 27.22 | 32.44 | 31.52 | 67.37 | 17.4 | 5.174 |
| Enterprise Value (EV) 1 | -10.2 | 6.051 | 19.76 | 45.89 | 3.418 | -1.558 |
| P/E ratio | -1.55 x | -2.27 x | -2.76 x | -4.09 x | -1.79 x | -0.96 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 30.3 x | 11.9 x | 5.11 x | 262 x | 43.2 x | 9.76 x |
| EV / Revenue | -11.4 x | 2.22 x | 3.21 x | 179 x | 8.48 x | -2.94 x |
| EV / EBITDA | 0.51 x | -0.34 x | -1.4 x | -3.6 x | -0.31 x | 0.22 x |
| EV / FCF | 0.96 x | -0.74 x | -1.73 x | -13.8 x | -0.7 x | 0.25 x |
| FCF Yield | 104% | -135% | -57.9% | -7.25% | -142% | 404% |
| Price to Book | 0.74 x | 1.39 x | 2.38 x | 3.56 x | 1.76 x | 1.02 x |
| Nbr of stocks (in thousands) | 31,646 | 31,646 | 31,834 | 56,856 | 57,064 | 57,174 |
| Reference price 2 | 0.8600 | 1.025 | 0.9900 | 1.185 | 0.3050 | 0.0905 |
| Announcement Date | 7/31/18 | 8/3/19 | 8/19/20 | 8/17/21 | 8/16/22 | 6/16/23 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.897 | 2.72 | 6.165 | 0.257 | 0.403 | 0.53 |
| EBITDA 1 | -20.14 | -18 | -14.12 | -12.73 | -11 | -6.945 |
| EBIT 1 | -20.38 | -18.28 | -14.41 | -12.99 | -11.23 | -7.115 |
| Operating Margin | -2,271.57% | -672.13% | -233.72% | -5,055.25% | -2,786.1% | -1,342.45% |
| Earnings before Tax (EBT) 1 | -20.97 | -17.18 | -13.86 | -13.41 | -11.06 | -6.657 |
| Net income 1 | -17.62 | -14.29 | -11.41 | -11.35 | -9.689 | -5.408 |
| Net margin | -1,963.77% | -525.44% | -185.11% | -4,415.18% | -2,404.22% | -1,020.38% |
| EPS 2 | -0.5566 | -0.4516 | -0.3587 | -0.2900 | -0.1701 | -0.0947 |
| Free Cash Flow 1 | -10.58 | -8.159 | -11.44 | -3.328 | -4.868 | -6.299 |
| FCF margin | -1,180.04% | -299.97% | -185.51% | -1,294.94% | -1,207.97% | -1,188.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 7/31/18 | 8/3/19 | 8/19/20 | 8/17/21 | 8/16/22 | 6/16/23 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 37.4 | 26.4 | 11.8 | 21.5 | 14 | 6.73 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -10.6 | -8.16 | -11.4 | -3.33 | -4.87 | -6.3 |
| ROE (net income / shareholders' equity) | -39.2% | -47.6% | -62.6% | -70.6% | -67.3% | -72.4% |
| ROA (Net income/ Total Assets) | -25.1% | -31.1% | -34.7% | -35.5% | -32.9% | -33% |
| Assets 1 | 70.18 | 45.95 | 32.88 | 31.95 | 29.46 | 16.4 |
| Book Value Per Share 2 | 1.160 | 0.7400 | 0.4200 | 0.3300 | 0.1700 | 0.0900 |
| Cash Flow per Share 2 | 0.8800 | 0.6500 | 0.4000 | 0.2600 | 0.1700 | 0.1100 |
| Capex 1 | 0.24 | 0.19 | 0.12 | 0.03 | 0.3 | 0.22 |
| Capex / Sales | 26.2% | 6.91% | 1.93% | 9.73% | 74.94% | 41.51% |
| Announcement Date | 7/31/18 | 8/3/19 | 8/19/20 | 8/17/21 | 8/16/22 | 6/16/23 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.57% | 2.4M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- RENE Stock
- Financials ReNeuron Group plc
